1-(3-Chlorophenyl)piperazine



1-(3-Chlorophenyl)piperazine (or meta-chlorophenylpiperazine, mCPP) is a piperazine-based 5-HT receptor agonist that has been used as a challenge drug in MDMA research. In the mid-2000s, it has shown up in legal alternatives to illegal stimulants in New Zealand, and pills sold as ecstasy in Europe and the United States.

mCPP is known to induce headaches in humans, and has been used for testing potential anti-migraine medications. Up to 10% of people who take mCPP will develop a migraine headache, and 90% of individuals who commonly suffer from migraines will have an attack induced by mCPP. This has tended to limit the use of mCPP as a recreational drug.

Legal status
In the US: unscheduled In New Zealand: unscheduled In Denmark: Banned In Germany: Banned